PERSONAL INFORMATION
Name: Qiuling Shi
Gender: Female
Title: Professor
Position: MD PhD
CONTACT INFORMATION
Email: qshi@cqmu.edu.cn
Address: 1 Yixueyuan Rd, Yuzhong Dist., Chongqing, China 400016
Phone: 0086-23-68486500（work）；0086-18290585397 (cell)
EDUCATION EXPERIENCE
Degree-Granting Education
The Fourth Military Medical University, PhD, 2000, Epidemiology.
The Fourth Military Medical University, MS,1997, Epidemiology.
West China University of Medical Science, MD,1994, Preventive Medicine.
Postgraduate Training
Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Postdoctoral Fellow, 09/2002 - 04/2005.
Department of Occupational Health, Chinese Center for Disease Prevention and Control, Postdoctoral Fellow, 09/2000 - 08/2002
Department of Community Health, The University of Hongkong, Mrs. Ivy Wu Fellow, 09/1998 to 03/1999.
WORKING EXPERIENCE
12-2019 to present State Key Laboratory of Ultrasound in Medicine and Engineering, School of Public Health, Chonqing Medical University, Professor.
09-2017 to 11-2019 Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Associate professor.
09-2009 to 08-2017 Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Assistant professor.
09-2006 to 08-2009 Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Instructor.
05-2005 to 08-2006 Department of Symptom Research, The University of Texas MD Anderson Cancer Center，Hahn Foundation Fellow.
RESEARCH INTERESTS
Prof. Shi supported clinical research in malignant tumors at M.D. Anderson Cancer Center from 2002 to 2019. Her main research interests include PRO clinical application methodology, real-world clinical data research, and intelligent clinical research management.
Dr. Qiuling Shi is a full professor in the Dept. of Epidemiology, School of Public Health at Chongqing Medical University. Dr. Shi also works full-time as the Deputy Chair of the Key State Laboratory of Ultrasound Engineering in Medcine.
Dr. Shi have devoted her career to promoting effective use of PROs into clinical practice in both US and China. After 17 years of service as a PRO researcher in the UT MD Anderson Cancer center, Dr. Shi is leading a Chinese team for surgical oncology research.
Dr. Shi has directed projects aimed at reducing the risk of inadequate symptom control in oncological practice; studies of developing utility parameters for implementing PROs into clinical research and practice; and studies of PRO trajectories over the course of cancer treatment. Prof. Shi has published more than 40 papers in Nature Medicine, JCO, etc. as the first or corresponding author. In 2020, Prof. Shi's team evaluated the effectiveness of viral control measures in Wanzhou and successfully published the results in Nature Medcine. In addition, Prof. Shi was awarded the honorary title of "Advanced Individual in Fighting against New Crown Pneumonia Epidemic in Chongqing Municipality".
HONOUR & AWARDS
Administrative Appointments
Deputy Chair, State Key Laboratory of Ultrasound in Medicine and Engineering, 2020-present
Joint appointment
Professor, Sichuan Cancer Hospital, Chengdu, China, 12/2019-present
Other Appointments/Responsibilities
1.Deputy Chair, China Anti-cancer Association Society of Geriatric Oncology, 2021-present
2.Co-Chair, International Society for Quality of Life Research (ISOQOL) China Section.
3.Vice Chairman of the Third Committee of the Specialized Committee on Clinical Epidemiology of Chongqing Medical Association.
PUBLICATIONS
Peer-review articles (First/Corresponding author)
1.Zhang J, Su X, Xu W, Yu Q, Dai W, Wang Y, Zhuang X, Li Q, Wang XS, Shi Q. Identifying patients who suffered from post-discharge cough after lung cancer surgery. Support Care Cancer. 2022 Jun 13. doi: 10.1007/s00520-022-07197-x. Epub ahead of print. PMID: 35695932.
2.Xu W, Dai W, Gao Z, Wang XS, Tang L, Pu Y, Yu Q, Yu H, Nie Y, Zhuang W, Qiao G, Cleeland CS, Shi Q. Establishment of Minimal Clinically Important Improvement for Patient-Reported Symptoms to Define Recovery After Video-Assisted Thoracoscopic Surgery. Ann Surg Oncol. 2022 Apr 3. doi: 10.1245/s10434-022-11629-7. Epub ahead of print. PMID: 35368219.
3.Yu Q, Yu H, Xu W, Pu Y, Nie Y, Dai W, Wei X, Wang XS, Cleeland CS, Li Q, Shi Q. Shortness of Breath on Day 1 After Surgery Alerting the Presence of Early Respiratory Complications After Surgery in Lung Cancer Patients. Patient Prefer Adherence. 2022 Mar 19;16:709-722. doi: 10.2147/PPA.S348633. PMID: 35340757; PMCID: PMC8943684.
4.Sang G, Zhang X, Fan H, Ao X, Chen Y, Shi Q. Implementation of an enhanced recovery after surgery program in the treatment of uterine fibroids with focused ultrasound ablation surgery. Int J Hyperthermia. 2022;39(1):414-420. doi: 10.1080/02656736.2022.2037740. PMID: 35236194.
5.Zhang X, Xu W, Sang G, Yu D, Shi Q. A measure for perioperative anxiety symptoms in patients with FUAS - treated uterine fibroids: development and validation. Int J Hyperthermia. 2022;39(1):525-529. doi: 10.1080/02656736.2022.2051612. PMID: 35300541.
6.Li J, Huang C, Lin Z, Hu Y, Shi Q. Two MMP2 gene polymorphisms significantly associated with polycystic ovary syndrome: A case-control analysis. Eur J Obstet Gynecol Reprod Biol. 2022 Feb 24;271:204-209. doi: 10.1016/j.ejogrb.2022.02.019. Epub ahead of print. PMID: 35228091.
7.Dai W, Feng W, Zhang Y, Wang XS, Liu Y, Pompili C, Xu W, Xie S, Wang Y, Liao J, Wei X, Xiang R, Hu B, Tian B, Yang X, Wang X, Xiao P, Lai Q, Wang X, Cao B, Wang Q, Liu F, Liu X, Xie T, Yang X, Zhuang X, Wu Z, Che G, Li Q, Shi Q. Patient-Reported Outcome-Based Symptom Management Versus Usual Care After Lung Cancer Surgery: A Multicenter Randomized Controlled Trial. J Clin Oncol. 2022 Mar 20;40(9):988-996. doi: 10.1200/JCO.21.01344. Epub 2022 Jan 7. PMID: 34995100; PMCID: PMC8937008..
8.Wei X, Yu H, Dai W, Xu W, Yu Q, Pu Y, Wang Y, Liao J, Li Q, Shi Q. Discrepancy in the perception of symptoms among patients and healthcare providers after lung cancer surgery. Support Care Cancer. 2021 Aug 27. doi: 10.1007/s00520-021-06506-0. Epub ahead of print. PMID: 34448942.
9.Xu F, Deng L, Zhang L, Hu H, Shi Q. The comparison of myomectomy, UAE and MRgFUS in the treatment of uterine fibroids: a meta analysis. Int J Hyperthermia. 2021 Sep;38(2):24-29. doi: 10.1080/02656736.2021.1933216. PMID: 34420449.
10.Feng Y, Dai W, Wang Y, Liao J, Wei X, Xie S, Xu W, Li Q, Liu F, Shi Q. Comparison of Chief Complaints and Patient-Reported Symptoms of Treatment-Naive Lung Cancer Patients Before Surgery. Patient Prefer Adherence. 2021 May 25;15:1101-1106. doi: 10.2147/PPA.S307814. PMID: 34079230; PMCID: PMC8164718.
11.Wei X, Yu H, Dai W, Mu Y, Wang Y, Liao J, Peng L, Han Y, Li Q, Shi Q. Patient-Reported Outcomes of Video-Assisted Thoracoscopic Surgery Versus Thoracotomy for Locally Advanced Lung Cancer: A Longitudinal Cohort Study. Ann Surg Oncol. 2021 Apr 20. doi: 10.1245/s10434-021-09981-1. Epub ahead of print. Erratum in: Ann Surg Oncol. 2021 Sep 24;: PMID: 33880671.
12.Xu W, Huang J, Yu Q, Yu H, Pu Y, Shi Q. A systematic review of the status and methodological considerations for estimating risk of first ever stroke in the general population. Neurol Sci. 2021 Jun;42(6):2235-2247. doi: 10.1007/s10072-021-05219-w. Epub 2021 Mar 30. PMID: 33783660.
13.Xu F, Li F, Li L, Lin D, Hu H, Shi Q. Vitamin D as a risk factor for the presence of asymptomatic uterine fibroids in premenopausal Han Chinese women. Fertil Steril. 2021 May;115(5):1288-1293. doi: 10.1016/j.fertnstert.2020.12.001. Epub 2021 Feb 12. PMID: 33589134.
14.Shi Q, Hu Y, Peng B, Tang XJ, Wang W, Su K, Luo C, Wu B, Zhang F, Zhang Y, Anderson B, Zhong XN, Qiu JF, Yang CY, Huang AL. Effective control of SARS-CoV-2 transmission in Wanzhou, China. Nat Med. 2021 Jan;27(1):86-93. doi: 10.1038/s41591-020-01178-5. Epub 2020 Nov 30. PMID: 33257893.
15.Shi Q, Lee JW, Wang XS, Fisch MJ, Chang VT, Wagner L, Cleeland CS. Testing Symptom Severity Thresholds and Potential Alerts for Clinical Intervention in Patients With Cancer Undergoing Chemotherapy. JCO Oncol Pract. 2020 Sep;16(9):e893-e901 . doi: 10.1200/JOP.19.00403. Epub 2020 May 5. PMID: 32369412; PMCID: PMC7489487.
16.Dai W, Zhang Y, Feng W, Liao X, Mu Y, Zhang R, Wei X, Wu C, Xie S, Li Q, Shi Q BMJ Open. 2019 Aug 26;9(8):e030041. doi: 10.1136/bmjopen-2019-030041.
17.Dai W, Xie S, Zhang R, Wei X, Wu C, Zhang Y, Feng W, Liao X, Mu Y, Zhou H, Cheng X, Jiang Y, He J, Li Q, Yang X, Shi Q. Developing and validating utility parameters to establish patient-reported outcome-based perioperative symptom management in patients with lung cancer: a multicentre, prospective, observational cohort study protocol. BMJ Open. 2019 Oct 28;9(10):e030726. doi: 10.1136/bmjopen-2019-030726. PMID: 31662377; PMCID: PMC6830688.
18.Shi Q, Mendoza TR, Cleeland CS. Interpreting Patient-reported Outcome Scores for Clinical Research and Practice: Definition, Determination, and Application of Cutpoints. Med Care 57 Suppl 5 Suppl 1:S8-S12, 5/2019. PMID: 30985590.
19.Shi Q, Mendoza TR, Dueck AC, Ma H, Zhang J, Qian Y, Bhowmik D, Cleeland CS. Determination of mild, moderate, and severe pain interference in patients with cancer. Pain 158(6):1108-1112, 6/2017. PMID: 28267060.
20.Shi Q, Mendoza TR, Wang XS, Cleeland CS. Using a symptom-specific instrument to measure patient-reported daily functioning in patients with cancer. Eur J Cancer 67:83-90, 11/2016. e-Pub 9/2016. PMID: 27620946.
21.Shi Q, Wang XS, Vaporciyan AA, Rice DC, Popat KU, Cleeland CS. Patient-reported symptom interference as a measure of postsurgery functional recovery in lung cancer. J Pain Symptom Manage 52(6):822-831, 12/2016. e-Pub 8/2016. PMCID: PMC5154813.
22.Shi Q, Wang XS, Li G, Shah ND, Orlowski RZ, Williams LA, Mendoza TR, Cleeland CS. Racial/ethnic disparities in inflammatory gene single-nucleotide polymorphisms as predictors of a high risk for symptom burden in patients with multiple myeloma 1 year after diagnosis. Cancer 121(7):1138-46, 4/2015. e-Pub 12/2014. PMCID: PMC4368488.
23.Shi Q, Wang XS, Mendoza TR, Pandya KJ, Cleeland CS. Assessing persistent cancer pain: a comparison of current-pain ratings and pain recalled from the past week. J Pain Symptom Manage 37(2):168-74, 2/2009. e-Pub 8/2008. PMCID: PMC2705174.
24.Shi Q, Cleeland CS, Klepstad P, Miaskowski C, Pedersen NL, GeneQOL Consortium. Biological pathways and genetic variables involved in pain. Qual Life Res 19(10):1407-17, 12/2010. e-Pub 9/2010. PMID: 20842532.
25.Shi Q, Duvic M, Osei JS, Hordinsky MK, Norris DA, Price VH, Amos CI, Christiano AM, Mendoza TR. Health-related quality of life (HRQoL) in alopecia areata patients-a secondary analysis of the National Alopecia Areata Registry Data. J Investig Dermatol Symp Proc 16(1):S49-50, 12/2013. PMID: 24326555.
26.Shi Q, Giordano SH, Lu H, Saleeba AK, Malveaux D, Cleeland CS. Anastrozole-associated joint pain and other symptoms in patients with breast cancer. J Pain 14(3):290-6, 3/2013. PMCID: PMC3587979.
27.Shi Q, Mendoza TR, Gunn GB, Wang XS, Rosenthal DI, Cleeland CS. Using group-based trajectory modeling to examine heterogeneity of symptom burden in patients with head and neck cancer undergoing aggressive non-surgical therapy. Qual Life Res 22(9):2331-9, 11/2013. e-Pub 3/2013. PMCID: PMC3718875.
28.Shi Q, Smith TG, Michonski JD, Stein KD, Kaw C, Cleeland CS. Symptom burden in cancer survivors 1 year after diagnosis: a report from the American Cancer Society's Studies of Cancer Survivors. Cancer 117(12):2779-90, 6/2011. e-Pub 4/2011. PMCID: PMC3143572.
29.Shi Q， Trask PC, Wang XS, Mendoza TR, Apraku WA, Malekifar M, Cleeland CS. Does recall period have an effect on cancer patients' ratings of the severity of multiple symptoms? J Pain Symptom Manage 40(2):191-9, 8/2010. e-Pub 6/2010. PMID: 20579835.
30.Shi Q, Langer G, Cohen J, Cleeland CS. People in pain: How do they seek relief? J Pain 8(8):624-36, 8/2007. e-Pub 6/2007. PMID: 17586099.
31.Shi Q, Wang LE, Bondy ML, Brewster A, Singletary SE, Wei Q. Reduced DNA repair of benzo[a]pyrene diol epoxide-induced adducts and common XPD polymorphisms in breast cancer patients. Carcinogenesis 25(9):1695-700, 9/2004. e-Pub 4/2004. PMID: 15090466.
32.Shi Q, Zhang Z, Li G, Pillow PC, Hernandez LM, Spitz MR, Wei Q. Polymorphisms of methionine synthase and methionine synthase reductase and risk of lung cancer: a case-control analysis. Pharmacogenet Genomics 15(8):547-55, 8/2005. PMID: 16006998.
33.Shi Q, Zhang Z, Li G, Pillow PC, Hernandez LM, Spitz MR, Wei Q. Sex differences in risk of lung cancer associated with methylene-tetrahydrofolate reductase polymorphisms. Cancer Epidemiol Biomarkers Prev 14(6):1477-84, 6/2005. PMID: 15941959. (IF=4.344)
34.Shi Q, Zhang Z, Neumann AS, Li G, Spitz MR, Wei Q. Case-control analysis of thymidylate synthase polymorphisms and risk of lung cancer. Carcinogenesis 26(3):649-56, 3/2005. e-Pub 12/2004. PMID: 15579479.
35.Shi Q, Zheng Y, Zheng S, Xiao C, Leng S. He F. Cyclin D1 gene polymorphism and susceptibility to lung cancer in a Chinese population. Carcinogenesis 24(9):1499-503, 9/2003. e-Pub 3/2003. PMID: 12807740.
Peer-review articles (co-author)
1.Dai W, Chang S, Pompili C, Qiu B, Wei X, Mu Y, Zhang R, Shen C, Shi Q, Li Q, Wu Z, Che G. Early Postoperative Patient-Reported Outcomes After Thoracoscopic Segmentectomy Versus Lobectomy for Small-Sized Peripheral Non-small-cell Lung Cancer. Ann Surg Oncol. 2022 Jan;29(1):547-556. doi: 10.1245/s10434-021-10946-7. Epub 2021 Nov 6. PMID: 34743281.
2.Zhuang W, Zhang J, Wei P, Lan Z, Chen R, Zeng C, Shi Q, Qiao G. Misconception contributed to COVID-19 vaccine hesitancy in patients with lung cancer or ground-glass opacity: a cross-sectional study of 324 Chinese patients. Hum Vaccin Immunother. 2021 Oct 29:1-8. doi: 10.1080/21645515.2021.1992212. Epub ahead of print. PMID: 34715002.
3.Dai W, Dai Z, Wei X, Pompili C, Shi Q, Xie TP, He JT, Li Q. Early Patient-Reported Outcomes After Uniportal Versus Multiportal Thoracoscopic Lobectomy. Ann Thorac Surg. 2021 Sep 29:S0003-4975(21)01674-X. doi: 10.1016/j.athoracsur.2021.08.058. Epub ahead of print. PMID: 34599909.
4.Wang XS, Shi Q, Williams LA, Lillemoe HA, Chen TY, Gottumukkala V, Garcia-Gonzalez A, Malveaux D, Kamal M, Cleeland CS, Aloia TA. Development of a patient-reported outcome tool for assessing symptom burden during perioperative care in liver surgery: The MDASI-PeriOp-Hep. Eur J Oncol Nurs. 2021 Jun;52:101959. doi: 10.1016/j.ejon.2021.101959. Epub 2021 Apr 28. PMID: 33964632.
5.Huang S, Zhuang W, Wang D, Zha L, Xu X, Li X, Shi Q, Wang XS, Qiao G. Persistent Somatic Symptom Burden and Sleep Disturbance in Patients with COVID-19 During Hospitalization and After Discharge: A Prospective Cohort Study. Med Sci Monit. 2021 Apr 15;27:e930447. doi: 10.12659/MSM.930447. PMID: 33854028; PMCID: PMC8057653.
6.Wang XS, Shi Q, Mendoza TR, Garcia-Gonzalez A, Chen TY, Kamal M, Chen TH, Heijnen C, Orlowski RZ, Cleeland CS. Minocycline for symptom reduction in patients with multiple myeloma during maintenance therapy: a phase II placebo-controlled randomized trial. Support Care Cancer. 2021 Oct;29(10):6099-6107. doi: 10.1007/s00520-021-06110-2. Epub 2021 Apr 1. PMID: 33792800.
7.Wang XS, Kamal M, Chen TH, Shi Q, Garcia-Gonzalez A, Iniesta MD, Cleeland CS, Gottumukkala V, Meyer LA. Assessment of physical function by subjective and objective methods in patients undergoing open gynecologic surgery. Gynecol Oncol. 2021 Apr;161(1):83-88. doi: 10.1016/j.ygyno.2021.01.021. Epub 2021 Jan 31. PMID: 33536127; PMCID: PMC7994186.
8.Hillman RT, Iniesta MD, Shi Q, Suki T, Chen T, Cain K, Williams L, Wang XS, Taylor JS, Mena G, Lasala J, Ramirez PT, Meyer LA. Longitudinal patient-reported outcomes and restrictive opioid prescribing after minimally invasive gynecologic surgery. Int J Gynecol Cancer. 2021 Jan;31(1):114-121. doi: 10.1136/ijgc-2020-002103. Epub 2020 Nov 6. PMID: 33158876.
9.Hillman RT, Iniesta MD, Shi Q, Suki T, Chen T, Cain K, Williams L, Wang XS, Taylor JS, Mena G, Lasala J, Ramirez PT, Meyer LA. Longitudinal patient-reported outcomes and restrictive opioid prescribing after minimally invasive gynecologic surgery. Int J Gynecol Cancer. 2021 Jan;31(1):114-121. doi: 10.1136/ijgc-2020-002103. Epub 2020 Nov 6. PMID: 33158876.
10.Whisenant MS, Williams LA, Garcia Gonzalez A, Mendoza T, Shi Q, Cleeland C, Zhang J, Heymach J, Simon G. What Do Patients With Non-Small-Cell Lung Cancer Experience? Content Domain for the MD Anderson Symptom Inventory for Lung Cancer. JCO Oncol Pract. 2020 Oct;16(10):e1151-e1160. doi: 10.1200/JOP.19.00577. Epub 2020 Jun 15. PMID: 32539654.
11.Kamal M, Wang XS, Shi Q, Zyczynski TM, Davis C, Williams LA, Lin HK, Garcia-Gonzalez A, Cleeland CS, Orlowski R. Symptom burden and its functional impact in patients with "symptomatic" relapsed or refractory multiple myeloma. Support Care Cancer. 2021 Jan;29(1):467-475. doi: 10.1007/s00520-020-05493-y. Epub 2020 May 11. PMID: 32390093.
12.Kamal M, Wang XS, Shi Q, Mendoza T, Garcia-Gonzalez A, Bokhari RH, Cleeland CS, Fogelman DR. A Randomized, Placebo-Controlled, Double-Blind Study of Minocycline for Reducing the Symptom Burden Experienced by Patients With Advanced Pancreatic Cancer. J Pain Symptom Manage. 2020 May;59(5):1052-1058.e1. doi: 10.1016/j.jpainsymman.2020.01.007. Epub 2020 Jan 24. PMID: 31982605; PMCID: PMC7249481.
13.Cleeland CS, Wang XS, Shi Q, Mendoza TR, Wright SL, Berry MD, Malveaux D, Shah PK, Gning I, Hofstetter WL, Putnam JB, Vaporciyan AA. Automated symptom alerts reduce postoperative symptom severity after cancer surgery: a randomized controlled clinical trial. J Clin Oncol 29(8):994-1000, 3/2011. e-Pub 1/2011. PMCID: PMC3068055.
14.Gomez DR, Blumenschein GR, Lee JJ, Hernandez M, Ye R, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Gibbons DL, Karam JA, Kavanagh BD, Tang C, Komaki R, Louie AV, Palma DA, Tsao AS, Sepesi B, William WN, Zhang J, Shi Q, Wang XS, Swisher SG, Heymach JV. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol 17(12):1672-1682, 12/2016. e-Pub 10/2016.
15.Aloia TA, Kim BJ, Segraves-Chun YS, Cata JP, Truty MJ, Shi Q, Holmes A, Soliz JM, Popat KU, Rahlfs TF, Lee JE, Wang XS, Morris JS, Gottumukkala VNR, Vauthey JN. A randomized controlled trial of postoperative thoracic epidural analgesia versus intravenous patient-controlled analgesia after major hepatopancreatobiliary surgery. Ann Surg 266(3):545-554, 9/2017. PMCID: PMC5784834.
16.Meyer LA, Corzo C, Iniesta MD, Munsell M, Shi Q, Pitcher B, Lasala J, Cain KE, Wang XS, Mena G, Ramirez PT. A prospective randomized trial comparing liposomal bupivacaine vs standard bupivacaine wound infiltration in open gynecologic surgery on an enhanced recovery pathway. Am J Obstet Gynecol. 2020 Jul 16:S0002-9378(20)30738-9. doi: 10.1016/j.ajog.2020.07.017. Epub ahead of print. PMID: 32682856.
17.Wang XS, Shi Q, Mendoza T, Lin S, Chang JY, Bokhari RH, Lin HK, Garcia-Gonzalez A, Kamal M, Cleeland CS, Liao Z. Minocycline Reduces Chemoradiation-Related Symptom Burden in Patients with Non-Small Cell Lung Cancer: A Phase 2 Randomized Trial. Int J Radiat Oncol Biol Phys. 2020 Jan 1;106(1):100-107. doi: 10.1016/j.ijrobp.2019.10.010. Epub 2019 Oct 15. PMID: 31627177; PMCID: PMC7043289.
18.Aggarwal P, Zaveri JS, Goepfert RP, Shi Q, Du XL, Swartz M, Gunn GB, Lai SY, Fuller CD, Hanna EY, Rosenthal DI, Lewin JS, Piller LB, Hutcheson KA. Symptom burden associated with late lower cranial neuropathy in long-term oropharyngeal cancer survivors. JAMA Otolaryngol Head Neck Surg 144(11):1066-1076, 11/2018. e-Pub 9/2018. PMCID: PMC6248190. (IF=3.848)
19.Fagundes CP, Shi Q, Vaporciyan AA, Rice DC, Popat KU, Cleeland CS, Wang XS. Symptom recovery after thoracic surgery: Measuring patient-reported outcomes with the MD Anderson Symptom Inventory. J Thorac Cardiovasc Surg 150(3):613-9.e2, 9/2015. e-Pub 5/2015. PMCID: PMC4554973.
20.Gunn GB, Mendoza TR, Garden AS, Wang XS, Shi Q, Morrison WH, Frank SJ, Phan J, Fuller CD, Chambers MS, Hanna EY, Lu C, Rosenthal DI, Cleeland CS. Minocycline for symptom reduction during radiation therapy for head and neck cancer: a randomized clinical trial. Support Care Cancer. e-Pub 4/2019. PMID: 31037378.
21.Kukreja JB, Shi Q, Chang CM, Seif MA, Sterling BM, Chen TY, Creel KM, Kamat AM, Dinney CP, Navai N, Shah JB, Wang XS. Patient-reported outcomes are associated with enhanced recovery status in patients with bladder cancer undergoing radical cystectomy. Surg Innov 25(3):242-250, 6/2018. e-Pub 3/2018. PMCID: PMC5995564.
22.Mendoza TR, Dueck AC, Shi Q, Ma H, Zhang J, Qian Y, Cleeland CS. The contribution of pain in determining the health status of cancer patients with bone metastases: A secondary analysis of data from three Phase III registration trials. Eur J Pain 22(3):565-571, 3/2018. e-Pub 10/2017. PMID: 29082574.
23.Mendoza TR, Kehl KL, Bamidele O, Williams LA, Shi Q, Cleeland CS, Simon G. Assessment of baseline symptom burden in treatment-naïve patients with lung cancer: an observational study. Support Care Cancer. e-Pub 1/2019. PMID: 30661202.
24.Mendoza TR, Osei JS, Shi Q, Duvic M. Development of the alopecia areata symptom impact scale. J Investig Dermatol Symp Proc 16(1):S51-2, 12/2013. PMID: 24326557.
25.Mendoza TR, Wang XS, Williams LA, Shi Q, Vichaya EG, Dougherty PM, Thomas SK, Yucel E, Bastida CC, Woodruff JF, Cleeland CS. Measuring therapy-induced peripheral neuropathy: preliminary development and validation of the Treatment-induced Neuropathy Assessment Scale (TNAS). J Pain 16(10):1032-43, 10/2015. e-Pub 7/2015. PMCID: PMC4592444.
26.Meyer LA, Lasala J, Iniesta MD, Nick AM, Munsell MF, Shi Q, Wang XS, Cain KE, Lu KH, Ramirez PT. Effect of an enhanced recovery after surgery program on opioid use and patient-reported outcomes. Obstet Gynecol 132(2):281-290, 8/2018. e-Pub 7/2018. PMCID: PMC6245646.
27.Meyer LA, Nick AM, Shi Q, Wang XS, Williams L, Brock T, Iniesta MD, Rangel K, Lu KH, Ramirez PT. Perioperative trajectory of patient reported symptoms: a pilot study in gynecologic oncology patients. Gynecol Oncol 136(3):440-5, 3/2015. e-Pub 1/2015. PMCID: PMC4711289.
28.Meyer LA, Shi Q, Lasala J, Iniesta MD, Lin HK, Nick AM, Williams L, Sun C, Wang XS, Lu KH, Ramirez PT. Comparison of patient reported symptom burden on an enhanced recovery after surgery (ERAS) care pathway in patients with ovarian cancer undergoing primary vs. interval tumor reductive surgery. Gynecol Oncol 152(3):501-508, 3/2019. PMCID: PMC6422048.
29.Murdock KW, Wang XS, Shi Q, Cleeland CS, Fagundes CP, Vernon SD. The utility of patient reported outcome measures among patients with myalgic encephalomyelitis/chronic fatigue syndrome. Qual Life Res 26(4):913-921, 4/2017. e-Pub 9/2016. PMCID: PMC5336422.
30.Shah N, Shi Q, Giralt S, Williams L, Bashir Q, Qazilbash M, Champlin RE, Cleeland CS, Wang XS. Utility of a patient-reported outcome in measuring functional impairment during autologous stem cell transplant in patients with multiple myeloma. Qual Life Res 27(4):979-985, 4/2018. e-Pub 12/2017. PMID: 29260444.
31.Shah N, Shi Q, Williams LA, Mendoza TR, Wang XS, Reuben JM, Dougherty PM, Bashir Q, Qazilbash MH, Champlin RE, Cleeland CS, Giralt SA. Higher stem cell dose infusion after intensive chemotherapy does not improve symptom burden in older patients with multiple myeloma and amyloidosis. Biol Blood Marrow Transplant 22(2):226-31, 2/2016. e-Pub 8/2015. PMCID: PMC4716870.
32.Sio TT, Lin HK, Shi Q, Gunn GB, Cleeland CS, Lee JJ, Hernandez M, Blanchard P, Thaker NG, Phan J, Rosenthal DI, Garden AS, Morrison WH, Fuller CD, Mendoza TR, Mohan R, Wang XS, Frank SJ. Intensity modulated proton therapy versus intensity modulated photon radiation therapy for oropharyngeal cancer: first comparative results of patient-reported outcomes. Int J Radiat Oncol Biol Phys 95(4):1107-14, 7/2016. e-Pub 2/2016. PMID: 27354125.
33.Sprangers MA, Sloan JA, Barsevick A, Chauhan C, Dueck AC, Raat H, Shi Q, Van Noorden CJ. Scientific imperatives, clinical implications, and theoretical underpinnings for the investigation of the relationship between genetic variables and patient-reported quality-of-life outcomes. Qual Life Res 19(10):1395-1403, 12/2010. PMCID: PMC2977054.
34.Sprangers MA, Sloan JA, Veenhoven R, Cleeland CS, Halyard MY, Abertnethy AP, Baas F, Barsevick AM, Bartels M, Boomsma DI, Chauhan C, Dueck AC, Frost MH, Hall P, Klepstad P, Martin NG, Miaskowski C, Mosing M, Movsas B, Van Noorden CJ, Patrick DL, Pedersen NL, Ropka ME, Shi Q, Shinozaki G, Singh JA, Yang P, Zwinderman AH. The establishment of the GENEQOL consortium to investigate the genetic disposition of patient-reported quality-of-life outcomes. Twin Res Hum Genet 12(3):301-11, 6/2009. PMID: 19456223.
35.Sprangers MA, Thong MS, Bartels M, Barsevick A, Ordoñana J, Shi Q, Wang XS, Klepstad P, Wierenga EA, Singh JA, Sloan JA, GeneQol Consortium. Biological pathways, candidate genes, and molecular markers associated with quality-of-life domains: an update. Qual Life Res 23(7):1997-2013, 9/2014. e-Pub 3/2014. PMCID: PMC4199387.
36.Wang L, Lu J, An J, Shi Q, Spitz MR, Wei Q. Polymorphisms of cytosolic serine hydroxymethyltransferase and risk of lung cancer: A case-control analysis. Lung Cancer 57(2):143-51, 8/2007. e-Pub 4/2007. PMCID: PMC2693017.
37.Wang L, Wei Q, Shi Q, Guo Z, Qiao Y, Spitz MR. A modified host-cell reactivation assay to measure repair of alkylating DNA damage for assessing risk of lung adenocarcinoma. Carcinogenesis 28(7):1430-6, 7/2007. e-Pub 3/2007. PMID: 17341660.
38.Wang XS, Shi Q, Bhadkamkar N, Cleeland CS, Garcia-Gonzalez A, Aguilar J, Heijnen C, Eng C. Minocycline for Symptom Reduction during Oxaliplatin-Based Chemotherapy for Colorectal Cancer: A Phase II Randomized Clinical Trial. J Pain Symptom Manage. e-Pub 6/2019. PMID: 31254639.
39.Wang XS, Shi Q, Dougherty PM, Eng C, Mendoza TR, Williams LA, Fogelman DR, Cleeland CS. Prechemotherapy touch sensation deficits predict oxaliplatin-induced neuropathy in patients with colorectal cancer. Oncology 90(3):127-35, 2016. e-Pub 2/2016. PMCID: PMC4794365.
40.Wang XS, Shi Q, Lu C, Basch EM, Johnson VE, Mendoza TR, Mobley GM, Cleeland CS. Prognostic value of symptom burden for overall survival in patients receiving chemotherapy for advanced non-small cell lung cancer. Cancer 116(1):137-45, 1/2010. e-Pub 10/2009. PMID: 19852033.
41.Wang XS, Shi Q, Shah ND, Heijnen CJ, Cohen EN, Reuben JM, Orlowski RZ, Qazilbash MH, Johnson VE, Williams LA, Mendoza TR, Cleeland CS. Inflammatory markers and development of symptom burden in patients with multiple myeloma during autologous stem cell transplantation. Clin Cancer Res 20(5):1366-74, 3/2014. e-Pub 1/2014. PMCID: PMC3947467.
42.Wang XS, Shi Q, Williams LA, Cleeland CS, Garcia-Gonzalez A, Chen TY, Shahid DR, Ramirez PT, Iniesta MD, Siverand AM, Meyer LA. Validation and application of a module of the MD Anderson Symptom Inventory for measuring perioperative symptom burden in patients with gynecologic cancer (the MDASI-PeriOp-GYN). Gynecol Oncol 152(3):492-500, 3/2019. PMCID: PMC6422045.
43.Wang XS, Shi Q, Williams LA, Cleeland CS, Mobley GM, Reuben JM, Lee BN, Giralt SA. Serum interleukin-6 predicts the development of multiple symptoms at nadir of allogeneic hematopoietic stem cell transplantation. Cancer 113(8):2102-9, 10/2008. PMCID: PMC2633777.
44.Wang XS, Shi Q, Williams LA, Komaki R, Gomez DR, Lin SH, Chang JY, O'Reilly MS, Bokhari RH, Cox JD, Mohan R, Cleeland CS, Liao Z. Prospective study of patient-reported symptom burden in patients with non-small-cell lung cancer undergoing proton or photon chemoradiation therapy. J Pain Symptom Manage 51(5):832-8, 5/2016. e-Pub 2/2016. PMCID: PMC4875833.
45.Wang XS, Shi Q, Williams LA, Mao L, Cleeland CS, Komaki RR, Mobley GM, Liao Z. Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy. Brain Behav Immun 24(6):968-74, 8/2010. e-Pub 3/2010. PMCID: PMC2897921.
46.Wang XS, Shi Q, Williams LA, Shah ND, Mendoza TR, Cohen EN, Reuben JM, Cleeland CS, Orlowski RZ. Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma. Leuk Lymphoma 56(5):1-7, 5/2015. e-Pub 11/2014. PMCID: PMC4439386.
47.Wang XS, Williams LA, Krishnan S, Liao Z, Liu P, Mao L, Shi Q, Mobley GM, Woodruff JF, Cleeland CS. Serum sTNF-R1, IL-6, and the development of fatigue in patients with gastrointestinal cancer undergoing chemoradiation therapy. Brain Behav Immun 26(5):699-705, 7/2012. e-Pub 1/2012. PMCID: PMC3355215.
48.Yue J, McKeever M, Sio TT, Xu T, Huo J, Shi Q, Nguyen QN, Komaki R, Gomez DR, Pan T, Wang XS, Liao Z. Association of lung fluorodeoxyglucose uptake with radiation pneumonitis after concurrent chemoradiation for non-small cell lung cancer. Clin Transl Radiat Oncol 4:1-7, 6/2017. e-Pub 5/2017. PMCID: PMC5833918.
49.Yue J, Shi Q, Xu T, Jeter M, Chen TY, Komaki R, Gomez DR, Pan T, Cleeland CS, Liao Z, Wang XS. Patient-reported lung symptoms as an early signal of impending radiation pneumonitis in patients with non-small cell lung cancer treated with chemoradiation: an observational study. Qual Life Res 27(6):1563-1570, 6/2018. e-Pub 3/2018. PMCID: PMC5953814.
50.Zulbaran-Rojas A, Lin HK, Shi Q, Williams LA, George B, Garcia-Manero G, Jabbour E, O'Brien S, Ravandi F, Wierda W, Estrov Z, Borthakur G, Kadia T, Cleeland C, Cortes JE, Kantarjian H. A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors. Cancer Med 7(11):5457-5469, 11/2018. e-Pub 10/2018. PMCID: PMC6246941.
Book Chapters
1.Shi Q, Cleeland CS. Genetic approaches to treating and preventing symptoms in patients with cancer. In: Cancer Symptom Science: Measurement, Mechanisms, and Management. Ed(s) CS Cleeland, MJ Fisch, AJ Dunn. Cambridge University Press: Cambridge UK, 192-205, 2011.
2.Wang XS, Shi Q. Symptom Assessment, Patient-Reported Outcomes, and Quality of Life Considerations in Perioperative Care for Patients With Cancer. In: Perioperative Care of the Cancer Patient . Ed(s) Hagberg C., Nates J., Riedel B., Gottumukkala V., Buggy D. Elsevier USA, 2022
Presentation at international conference
1.(B205.3)Feeling better versus feeling good: interpreting pain relief using MCID and PASS for patients with lung cancer surgery. the 28th Annual Conference of the International Society for Quality of Life Research. Virtually, 12-28 October 2021.
2.(101.4) Identifying difficulties and most-interested findings for analyzing patient-reported outcome data from perioperative settings. International Society for Quality of Life Research, 27th Annual Conference 2020 , 19 – 23 October 2020, Virtual Event
3.(B204.10) The agreement of pain relief responders defined by various pain severity items from the Brief Pain Inventory. International Society for Quality of Life Research, 26th Annual Conference, 20 – 23 October 2019, San Diego, California, United States
4.(1127) Patient-reported symptom interference as a potential measure for tolerability of cancer treatment: evidence from ECOG-ACRIN SOAPP. International Society for Quality of Life Research, 25th Annual Conference, 24 – 27 October 2018, Dublin, Ireland
5.(301.1) Using patient-reported functional impairment to quantify tolerability of radiotherapy in patients with head and neck cancer. International Society for Quality of Life Research, 24th Annual Conference. 18 – 21 October 2017, Philadelphia, Pennsylvania, United States
6.(1049) Responsiveness of patient-reported outcomes in measuring impairment of physical functioning related to cancer treatment. International Society for Quality of Life Research, 23rd Annual Conference, 19 – 22 October 2016, Copenhagen, Denmark
7.(205.1) Determining meaningful cutpoints for the interference items of the MD Anderson Symptom Inventory. International Society for Quality of Life Research, 22nd Annual Conference, 21 – 24 October 2015, Vancouver, British Columbia, Canada.
8.(2008) Measuring functional domains with the EORTC QLQ-C30 and MDASI in patients with cancer. International Society for Quality of Life Research, 21st Annual Conference, 15 – 18 October 2014, Berlin, Germany
9.(204.3) Using cluster analysis to generate outcome variables for gene-symptom association study in cancer patients. International Society for Quality of Life Research, 20th Annual Conference, 9 – 12 October 2013, Miami, Florida, United States
10.(101.3) Using time to symptomatic recovery as an outcome measure for para-operative pain study. International Society for Quality of Life Research, 19th Annual Conference, 24 – 27 October 2012, Budapest, Hungary
11.(293) Comparative Validity, Reliability and Responsiveness of Single and Multiple Item Measurement of Pain in Breast Cancer Patients with Aromatase Inhibitor Therapy. International Society for Quality of Life Research, 18th Annual Conference 26 – 29 October 2011 Denver, Colorado, United States
12.19/1393/ Using Group-Based Trajectory Modeling to Examine Heterogeneity of Cancer-Related Symptoms. International Society for Quality of Life Research, 17th Conference London, England, October 27 – 30, 2010
